Press Release
Arcadia Biosciences (RKDA) Announces Third-Quarter 2020 Financial Results and Business Highlights
"I am pleased to report Arcadia has achieved a number of fundamental milestones, resulting in a stronger financial wherewithal to achieve our number one goal: driving near-term shareholder value by unlocking the full potential of our commercial-ready products," said
Continued Plavan, "Bioceres is the perfect commercial steward to advance the HB4 soybean into global markets, and we are delighted to share in the equity and revenue upside of the business while dedicating all of our time, attention and capital resources to the near-term scale-up of our GoodWheat and GoodHemp-branded products. With the formal
Recent Operating and Business Highlights
- Strategic Transactions with Bioceres Crop Solutions (BIOX). Arcadia today is announcing a series of strategic transactions with BIOX, including the sale of its membership interest in Verdeca, a soybean joint venture the two companies formed in 2012. In another transaction, Bioceres acquired license rights to Arcadia's GoodWheat technologies in South and
Central America , for which Arcadia will receive future royalties on all sales. Arcadia will also receive$6 million in cash, including reimbursement of transaction-related expenses and fees, with an additional$2 million in cash to be paid upon achievement by Verdeca of specific regulatory and commercial milestones. Arcadia also receives 1.875 million unregistered shares of BIOX common stock and trait royalties of up to$10 million on HB4 soybean sales. - Partnership with Three Farm Daughters to Develop and Market GoodWheat Products. In the third quarter, Arcadia announced a strategic business venture with Three Farm Daughters, a majority female-owned
North Dakota -based consumer food company, to develop and market food products using Arcadia's patented non-GMO GoodWheat technology. Since then, the companies have launched multiple Three Farm Daughters-branded food products, including pastas and flour, that leverage the enhanced nutritional profiles of GoodWheat ingredients. These products are now being sold regionally and through the company's e-commerce site: www.threefarmdaughters.com. - Acquisition of
Innovative Hemp Seed Breeding Company . Arcadia closed a transaction with Industrial Seed Innovations (ISI), anOregon -based industrial hemp breeding and seed company, to acquire its commercial and genetic assets, including seed varieties, germplasm library and intellectual property. ISI's popular Rogue andUmpqua seed varieties will become part of Arcadia's portfolio, alongside the company's GoodHemp line of genetically superior hemp seeds, transplants and extracts. The acquisition significantly broadens and accelerates commercialization of Arcadia's hemp-related breeding platform and establishes a breeding research and development facility in thePacific Northwest , a key hemp production area. - Collaboration with
Corner Foods to Bring GoodWheat toChina andIsrael . Arcadia's collaboration withCorner Foods , an affiliate ofCorner Capital Group , brings Arcadia's GoodWheat portfolio of non-GMO specialty wheat ingredients toChina and expanding in the future toIsrael . The partnership will introduce GoodWheat products directly to consumers inChina via popular e-commerce site TMall and cooking and lifestyle network Tastemade China. Together, these digital platforms reach an estimated 8 million consumers inChina per month. - Collaboration with
GoodMills to Sell GoodWheat inEurope . Through a collaboration with GoodMills Innovation, an affiliate ofGoodMills Group ,Europe's largest milling company, Arcadia plans to commercialize GoodWheat varieties acrossEurope , introducing uniquely healthy products for the retail, consumer and food service sectors beginning in 2021. GoodMills Innovation is recognized as one of the world's leading innovators in grain-based ingredients that are both highly functional and nutritional. - Global Scale-up Underway for HB4 Drought Resistant, Herbicide Tolerant Soybeans. Through its Verdeca joint venture with Bioceres Crop Solutions, Arcadia successfully harvested foundation seed to enable up to 90,000 hectares in preparation for regulatory approval from
China . Verdeca is also increasing breeding and new market development activities to access incremental geographies, includingBrazil and theU.S. - Expansion of Intellectual Property Protection for GoodWheat Portfolio. Arcadia strengthened its intellectual property and GoodWheat technology portfolio with five additional
U.S. patents in Q2. TheU.S. Patent and Trademark Office awarded the company two patents for extending the shelf life of whole wheat by minimizing hydrolytic and oxidative rancidity. The company also received notices of allowance for three additional patents extending earlier claims surrounding the extended shelf life of wheat and reduced gluten grains. The new patents bring the total number of patents in Arcadia's GoodWheat portfolio of non-GMO wheat varieties to 23. - Foundational Patents for Non-GMO Herbicide Tolerant Wheat. The Australian Patent Office granted patents to Arcadia covering herbicide tolerance in wheat, and the
U.S. Patent and Trademark Office issued a notice of allowance for the same technology, with patents pending in other territories. Arcadia's herbicide tolerant wheat technology can be an important tool in the hybrid breeding toolkit. This technology will serve as the foundation for future innovation and could open the door to development of a highly efficient hybrid wheat production system, which would transform the 200 million hectare global wheat industry. - Warrant Exercise Transaction Generated
$2.6M in Gross Proceeds. Arcadia strengthened its balance sheet through a warrant exercise transaction in the third quarter, providing additional cash resources to persevere through the headwinds of the COVID-19 pandemic.
|
|||||||||
Financial Snapshot |
|||||||||
(Unaudited) |
|||||||||
($ in thousands) |
|||||||||
Three Months Ended |
Nine Months Ended |
||||||||
2020 |
2019 |
Favorable/ (Unfavorable) |
2020 |
2019 |
Favorable/ (Unfavorable) |
||||
$ |
% |
$ |
% |
||||||
Total revenues |
314 |
392 |
(78) |
(20%) |
904 |
753 |
151 |
20% |
|
Total operating expenses |
7,895 |
6,585 |
(1,310) |
(20%) |
21,151 |
16,145 |
(5,006) |
(31%) |
|
Loss from operations |
(7,581) |
(6,193) |
(1,388) |
(22%) |
(20,247) |
(15,392) |
(4,855) |
(32%) |
|
Net loss attributable to common stockholders |
(6,391) |
(14,187) |
7,796 |
55% |
(13,553) |
(22,562) |
9,009 |
40% |
Revenues
In the third quarter of 2020, revenues were
Operating Expenses
In the third quarter of 2020, operating expenses were
Research and development (R&D) costs decreased by
General and administrative (SG&A) costs decreased by
Cost of product revenues increased by
Net Loss Attributable to Common Stockholders
Net loss attributable to common shareholders for the third quarter of 2020 was
Net loss attributable to common shareholders for the nine months ended
Conference Call and Webcast
The company has scheduled a conference call for
Interested participants can join the conference call using the following numbers:
|
+1-844-243-4690 |
International Dial-In: |
+1-225-283-0138 |
Passcode: |
1303009 |
A live webcast of the conference call will be available on the "Investors" section of Arcadia's website at www.arcadiabio.com. Following completion of the call, a recorded replay will be available on the company's investor website.
About
Safe Harbor Statement
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release and the accompanying conference call contain forward-looking statements about the company and its products, including statements relating to the collaboration with
LinkedIn: Arcadia Biosciences
Twitter: @ArcadiaAg
|
|||||||
Condensed Consolidated Balance Sheets |
|||||||
(Unaudited) |
|||||||
(In thousands, except share data) |
|||||||
|
|
||||||
Assets |
|||||||
Current assets: |
|||||||
Cash and cash equivalents |
$ |
10,201 |
$ |
8,417 |
|||
Short-term investments |
— |
16,915 |
|||||
Accounts receivable |
373 |
602 |
|||||
Inventories, net — current |
9,416 |
1,794 |
|||||
Prepaid expenses and other current assets |
1,204 |
712 |
|||||
Total current assets |
21,194 |
28,440 |
|||||
Restricted cash |
2,001 |
— |
|||||
Property and equipment, net |
3,484 |
1,799 |
|||||
Right of use asset |
6,013 |
1,963 |
|||||
Inventories, net — noncurrent |
461 |
364 |
|||||
|
301 |
- |
|||||
Intangible assets, net |
400 |
- |
|||||
Other noncurrent assets |
23 |
8 |
|||||
Total assets |
$ |
33,877 |
$ |
32,574 |
|||
Liabilities and stockholders' equity |
|||||||
Current liabilities: |
|||||||
Accounts payable and accrued expenses |
$ |
6,711 |
$ |
4,685 |
|||
Amounts due to related parties |
29 |
40 |
|||||
Debt — current |
705 |
24 |
|||||
Unearned revenue — current |
— |
42 |
|||||
Operating lease liability — current |
700 |
611 |
|||||
Other current liabilities |
263 |
306 |
|||||
Total current liabilities |
8,408 |
5,708 |
|||||
Debt — noncurrent |
2,548 |
107 |
|||||
Operating lease liability — noncurrent |
5,574 |
1,497 |
|||||
Common stock warrant liabilities |
3,065 |
14,936 |
|||||
Other noncurrent liabilities |
2,280 |
2,000 |
|||||
Total liabilities |
21,875 |
24,248 |
|||||
Commitments and contingencies (Note 14) |
|||||||
Stockholders' equity: |
|||||||
Common stock, |
51 |
49 |
|||||
Additional paid-in capital |
231,954 |
214,826 |
|||||
Accumulated other comprehensive income |
— |
1 |
|||||
Accumulated deficit |
(220,725) |
(207,171) |
|||||
Total |
11,280 |
7,705 |
|||||
Non-controlling interest |
722 |
621 |
|||||
Total stockholders' equity |
12,002 |
8,326 |
|||||
Total liabilities and stockholders' equity |
$ |
33,877 |
$ |
32,574 |
|
||||||||||||||
Condensed Consolidated Statements of Operations and Comprehensive Loss |
||||||||||||||
(Unaudited) |
||||||||||||||
(In thousands, except share and per share data) |
||||||||||||||
Three Months Ended |
Nine Months Ended |
|||||||||||||
2020 |
2019 |
2020 |
2019 |
|||||||||||
Revenues: |
||||||||||||||
Product |
$ |
245 |
$ |
216 |
$ |
630 |
$ |
485 |
||||||
License |
10 |
17 |
110 |
17 |
||||||||||
Royalty |
16 |
— |
58 |
— |
||||||||||
Contract research and government grants |
43 |
159 |
106 |
251 |
||||||||||
Total revenues |
314 |
392 |
904 |
753 |
||||||||||
Operating expenses: |
||||||||||||||
Cost of product revenues |
1,841 |
177 |
3,463 |
324 |
||||||||||
Research and development |
1,762 |
1,931 |
5,999 |
5,387 |
||||||||||
Selling, general and administrative |
4,292 |
4,477 |
11,689 |
10,434 |
||||||||||
Total operating expenses |
7,895 |
6,585 |
21,151 |
16,145 |
||||||||||
Loss from operations |
(7,581) |
(6,193) |
(20,247) |
(15,392) |
||||||||||
Interest expense |
(23) |
(3) |
(32) |
(3) |
||||||||||
Other income, net |
- |
119 |
83 |
339 |
||||||||||
Change in fair value of common stock warrant liabilities |
1,130 |
(7,777) |
6,212 |
(6,790) |
||||||||||
Loss on extinguishment of warrant liability |
(682) |
— |
(635) |
— |
||||||||||
Offering costs |
— |
(336) |
- |
(702) |
||||||||||
Net loss before income taxes |
(7,156) |
(14,190) |
(14,619) |
(22,548) |
||||||||||
Income tax benefit (provision) |
(9) |
3 |
(15) |
(14) |
||||||||||
Net loss |
(7,165) |
(14,187) |
(14,634) |
(22,562) |
||||||||||
Net loss attributable to non-controlling interest |
(774) |
— |
(1,081) |
— |
||||||||||
Net loss attributable to common stockholders |
$ |
(6,391) |
$ |
(14,187) |
$ |
(13,553) |
$ |
(22,562) |
||||||
Net loss per share attributable to common stockholders: |
||||||||||||||
Basic and diluted |
$ |
(0.60) |
$ |
(2.04) |
$ |
(1.42) |
$ |
(4.03) |
||||||
Weighted-average number of shares used in per share calculations: |
||||||||||||||
Basic and diluted |
10,719,618 |
6,942,612 |
9,570,259 |
5,596,545 |
||||||||||
Other comprehensive loss, net of tax |
||||||||||||||
Unrealized losses on available-for-sale securities |
— |
(1) |
(1) |
— |
||||||||||
Other comprehensive loss |
— |
(1) |
(1) |
— |
||||||||||
Comprehensive loss attributable to common stockholders |
$ |
(6,391) |
$ |
(14,188) |
$ |
(13,554) |
$ |
(22,562) |
|
|||||||
Condensed Consolidated Statements of Cash Flows |
|||||||
(Unaudited) |
|||||||
(In thousands) |
|||||||
Nine Months Ended |
|||||||
2020 |
2019 |
||||||
CASH FLOWS FROM OPERATING ACTIVITIES: |
|||||||
Net loss |
$ |
(14,634) |
$ |
(22,562) |
|||
Adjustments to reconcile net loss to cash used in operating activities: |
|||||||
Change in fair value of common stock warrant liabilities |
(6,212) |
6,790 |
|||||
Loss on extinguishment of warrant liability |
635 |
— |
|||||
Offering costs |
- |
702 |
|||||
Depreciation |
395 |
133 |
|||||
Lease amortization |
745 |
530 |
|||||
(Gain) Loss on disposal of equipment |
(8) |
1 |
|||||
Net amortization of investment premium |
(44) |
(121) |
|||||
Stock-based compensation |
1,844 |
1,870 |
|||||
Write-down of inventory and prepaid production costs |
3,063 |
— |
|||||
Changes in operating assets and liabilities: |
|||||||
Accounts receivable |
229 |
38 |
|||||
Unbilled revenue |
- |
3 |
|||||
Inventories |
(9,609) |
(1,411) |
|||||
Prepaid expenses and other current assets |
(1,157) |
(36) |
|||||
Other noncurrent assets |
(15) |
— |
|||||
Accounts payable and accrued expenses |
2,026 |
2,425 |
|||||
Amounts due to related parties |
(11) |
(1) |
|||||
Other current liabilities |
(43) |
3 |
|||||
Unearned revenue |
(42) |
(16) |
|||||
Operating lease payments |
(629) |
(534) |
|||||
Net cash used in operating activities |
(23,467) |
(12,186) |
|||||
CASH FLOWS FROM INVESTING ACTIVITIES: |
|||||||
Proceeds from sale of property and equipment |
8 |
1 |
|||||
Purchases of property and equipment |
(2,038) |
(878) |
|||||
Acquisitions, net of cash acquired |
(500) |
— |
|||||
Purchases of investments |
(1,292) |
(18,458) |
|||||
Proceeds from sales and maturities of investments |
18,250 |
18,050 |
|||||
Net cash provided by (used in) investing activities |
14,428 |
(1,285) |
|||||
CASH FLOWS FROM FINANCING ACTIVITIES: |
|||||||
Proceeds from issuance of common stock and warrants from |
9,372 |
7,500 |
|||||
Proceeds from borrowings |
3,108 |
— |
|||||
Payments of transaction costs relating to extinguishment of warrant liability |
(863) |
— |
|||||
Proceeds from issuance of common stock and warrants from Purchase Agreement |
— |
10,000 |
|||||
Payments of offering costs relating to |
— |
(776) |
|||||
Payments of offering costs relating to |
— |
(663) |
|||||
Payments of offering costs relating to |
— |
(24) |
|||||
Principal payments on notes payable |
(26) |
(2) |
|||||
Proceeds from the exercise of warrants |
— |
5,269 |
|||||
Proceeds from ESPP purchases |
51 |
21 |
|||||
Capital contributions received from non-controlling interest |
1,182 |
689 |
|||||
Net cash provided by financing activities |
12,824 |
22,014 |
|||||
Net increase in cash, cash equivalents and restricted cash |
3,785 |
8,543 |
|||||
Cash, cash equivalents and restricted cash — beginning of period |
8,417 |
11,998 |
|||||
Cash, cash equivalents and restricted cash — end of period |
$ |
12,202 |
$ |
20,541 |
|||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: |
|||||||
Cash paid for income taxes |
$ |
1 |
$ |
2 |
|||
Cash paid for interest |
$ |
7 |
$ |
— |
|||
NONCASH INVESTING AND FINANCING ACTIVITIES: |
|||||||
Fixed assets acquired with notes payable |
$ |
37 |
$ |
139 |
|||
Common stock warrants issued to placement agent and included in offering costs related to |
$ |
215 |
$ |
— |
|||
Common stock warrants issued to placement agent and included in offering costs related to |
$ |
101 |
$ |
— |
|||
Offering costs in accounts payable and accrued expenses at end of period |
$ |
— |
$ |
21 |
|||
Common stock warrants issued to placement agent and included in offering costs related to |
$ |
— |
$ |
86 |
|||
Common stock warrants issued to placement agent and included in offering costs related to |
$ |
— |
$ |
95 |
|||
Reclassification of common stock warrant liability balance with warrant exercises |
$ |
7,016 |
|||||
Right of use assets obtained in exchange for new operating lease liabilities |
$ |
4,157 |
$ |
2,328 |
|||
Purchases of fixed assets included in accounts payable and accrued expenses |
$ |
— |
$ |
6 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/arcadia-biosciences-rkda-announces-third-quarter-2020-financial-results-and-business-highlights-301171722.html
SOURCE
Press: Sara Geisner, Trailblaze, sara@trailblaze.co, Investors: Pam Haley, Chief Financial Officer, ir@arcadiabio.com